Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) - protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb).

Tengelmann C, Joos S, Kaußner Y, Malzahn U, Lunden L, Klug A, Häusler KG, Escales C, Maetzler W, Hügen K, Zolk O, Heuschmann PU, Förster C, Kaduszkiewicz H, Gágyor I

Open source

DOI
10.1186/s12879-023-08925-2
Published
2024 Jan 6
Container
BMC infectious diseases
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12879-023-08925-2,
  title = {Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) - protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb).},
  author = {Tengelmann C and Joos S and Kaußner Y and Malzahn U and Lunden L and Klug A and Häusler KG and Escales C and Maetzler W and Hügen K and Zolk O and Heuschmann PU and Förster C and Kaduszkiewicz H and Gágyor I},
  year = {2024},
  journal = {BMC infectious diseases},
  doi = {10.1186/s12879-023-08925-2},
  url = {https://doi.org/10.1186/s12879-023-08925-2}
}

RIS

TY  - JOUR
TI  - Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) - protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb).
AU  - Tengelmann C
AU  - Joos S
AU  - Kaußner Y
AU  - Malzahn U
AU  - Lunden L
AU  - Klug A
AU  - Häusler KG
AU  - Escales C
AU  - Maetzler W
AU  - Hügen K
AU  - Zolk O
AU  - Heuschmann PU
AU  - Förster C
AU  - Kaduszkiewicz H
AU  - Gágyor I
PY  - 2024
JO  - BMC infectious diseases
DO  - 10.1186/s12879-023-08925-2
UR  - https://doi.org/10.1186/s12879-023-08925-2
ER  - 

APA

C, T., S, J., Y, K., U, M., L, L., A, K., KG, H., C, E., W, M., K, H., O, Z., PU, H., C, F., H, K., & I, G. (2024). Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) - protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb).. BMC infectious diseases. https://doi.org/10.1186/s12879-023-08925-2

Source records